Lau Y.-L.Vessey S.J.R.Chan I.S.F.Lee T.-L.LI-MIN HUANGLee C.-Y.Lin T.-Y.Lee B.W.Kwan K.Kasim S.M.Chan C.Y.Kaplan K.M.Distefano D.J.Harmon A.L.Golie A.Hartzel J.Xu J.Li S.Matthews H.Sadoff J.C.Shaw A.2021-06-242021-06-2420020264-410Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0037178307&doi=10.1016%2fS0264-410X%2802%2900245-1&partnerID=40&md5=d56ee1286b4bc0b5966fb09f32ac0e1bhttps://scholars.lib.ntu.edu.tw/handle/123456789/566655This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX? [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (?50,000 plaque forming units (PFU), Group A or ?16,000PFU, Group B) or 1 dose of VARILRIX?, (?40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ?5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. ? 2002 Elsevier Science Ltd. All rights reserved.Immunogenicity; Varicella vaccination; Varicella zoster virus[SDGs]SDG3chickenpox vaccine; measles mumps rubella vaccine; mmr; varicella zoster vaccine; chickenpox vaccine; live vaccine; virus antibody; chickenpox; clinical trial; conference paper; controlled clinical trial; controlled study; death; double blind procedure; drug safety; drug tolerability; ecchymosis; enzyme linked immunosorbent assay; erythema; female; human; human experiment; immunogenicity; male; multicenter study; normal human; preschool child; priority journal; randomized controlled trial; rash; side effect; vaccination; Varicella zoster virus; virus titration; article; blood; comparative study; drug tolerance; immunology; infant; safety; Antibodies, Viral; Chickenpox Vaccine; Comparative Study; Double-Blind Method; Drug Tolerance; Enzyme-Linked Immunosorbent Assay; Female; Herpesvirus 3, Human; Human; Infant; Male; Safety; Support, Non-U.S. Gov't; Vaccines, Attenuated; Antibodies, Viral; Double-Blind Method; Drug Tolerance; Enzyme-Linked Immunosorbent Assay; Female; Herpesvirus 3, Human; Humans; Infant; Male; Safety; Vaccines, Attenuatedconference paper10.1016/S0264-410X(02)00245-1121269062-s2.0-0037178307